Phase 2 trial in 67 patients with active SLE: ianalumab vs placebo, added to standard therapy, more often achieved SRI-4 with steroid tapering at week 28 (44.1% vs 9.1%). Interim analysis; no rise in serious infections, more injection-site reactions.
RCTn = 67
Agmon-Levin et al. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment